首页 > 药物分析学报（英文版） > Pathogenesis and treatment strategies for infectious keratitis:Exploring antibiotics,antimicrobial peptides,nanotechnology,and emerging therapies

Pathogenesis and treatment strategies for infectious keratitis:Exploring antibiotics,antimicrobial peptides,nanotechnology,and emerging therapies

导出在线阅读解读下载全文终端阅读

二维码有效期 120s

点击刷新

注：终端设备浏览有效期：

学术成果认领

翻译打印收藏纠错

摘要Infectious keratitis(IK)is a leading cause of blindness worldwide,primarily resulting from improper contact lens use,trauma,and a compromised immune response.The pathogenic microorganisms responsible for IK include bacteria,fungi,viruses,and Acanthamoeba.This review examines standard therapeutic agents for treating IK,including broad-spectrum empiric antibiotics for bacterial keratitis(BK),antifungals such as voriconazole and natamycin for fungal infections,and antiviral nucleoside analogues for viral keratitis(VK).Additionally,this review discusses therapeutic agents,such as poly-hexamethylene biguanide(PHMB),for the treatment of Acanthamoeba keratitis(AK).The review also addresses emerging drugs and the challenges associated with their clinical application,including anti-biofilm agents that combat drug resistance and nuclear factor kappa-B(NF-κB)pathway-targeted ther-apies to mitigate inflammation.Furthermore,methods of Photodynamic Antimicrobial Therapy(PDAT)are explored.This review underscores the importance of integrating novel and traditional therapies to tackle drug resistance and enhance drug delivery,with the goal of advancing treatment strategies for IK.

作者 Man Yu ^[1] Ling Li ^[2] Yijun Liu ^[2] Ting Wang ^[2] Huan Li ^[2] Chen Shi ^[2] Xiaoxin Guo ^[3] Weijia Wu ^[2] Chengzi Gan ^[2] Mingze Li ^[2] Jiaxu Hong ^[4] Kai Dong ^[3] Bo Gong ^[5] 学术成果认领

作者单位 Department of Ophthalmology,Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,610072,China ^[1] Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine,Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,610072,China ^[2] Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine,Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,610072,China;Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences(2019RU026),Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,610072,China ^[3] Department of Ophthalmology,Eye & ENT Hospital,State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science,Fudan University,Shanghai,200031,China ^[4] Department of Ophthalmology,Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,610072,China;Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine,Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,610072,China;Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences(2019RU026),Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,610072,China ^[5]

关键词 Infectious keratitis Therapeutic drugs Antibiotic resistance Nanotechnology Antimicrobial peptides Emerging therapies

栏目名称

Review Papers

DOI 10.1016/j.jpha.2025.101250

发布时间 2026-01-27（万方平台首次上网日期，不代表论文的发表时间）

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交